ArticleInternational orthopaedics2025
Periprosthetic fracture in the setting of periprosthetic joint infection of the hip: evaluation and management of a single-centre cohort with forty six patients.
Article in International orthopaedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Management of infected periprosthetic fracture of hip and knee: a systematic review of the literature.EFORT open reviews · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsPeriprosthetic joint infection (PJI) and periprosthetic fracture (PPF) belong to the most devastating and complex complications following total hip arthroplasty, especially when both occur simultaneously. The aims of this study were (1) to evaluate the clinical outcome of PJI treatment in the setting of concomitant PPF and (2) to determine risk factors for reinfection.
methodsThis study retrospectively analysed PPF occurring during the treatment of PJI in total hip arthroplasty (THA). In total 46 THA were included with concomitant PJI and PPF, of which 28 fractures occurred during the explantation and 13 fractures occurred during the interval between explantation and reimplantation. The median follow-up period was 66 months (range: 24–90) and minimum follow up of at least two years. Patients without infection recurrence after their surgical management were considered to have a successful clinical outcome. Reinfections rates were estimated through Kaplan-Meier curve and potential risk factors for reinfection were analysed with univariate non-parametric tests. Multivariate Cox hazard regression was used in order to account for confounders.
resultsOverall, the success rate in our cohort was 71%. The overall mortality rate at follow-up was 22%. The estimated cumulative reinfection-free survival was 68% (95% CI = 80.9–50.5%) with a reinfection risk of 20% (95% CI = 10.3%-35.3%) in the first 12 months. Two patients (4.8%) had a re-fracture and another two (4.8%) had a recurrent hip dislocation that needed surgical intervention. High virulence pathogens (p = 0.038), difficult-to-treat pathogens (p = 0.016) and number of debridement during the interval (p = 0.043) were significant risk factors for reinfections. Difficult-to-treat pathogens were shown to be independent risk factors (p = 0.040).
conclusionThe reinfection rate of concomitant PJI and PPF is high and target treatment should be achieved. Significant risk factors for reinfection were presence of difficult-to-treat or highly virulent pathogens and increased number of debridement between explantation and reimplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.